Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors
Glaucoma, the leading cause of irreversible blindness, blinds causes irreversible blindness in 4.0 million people worldwide. In India the estimated number of glaucoma patients is 12 million which is one fifth of the global morbidity of glaucoma.1 Elevation of intraocular pressure (IOP) is the only p...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2020-04-01
|
| Series: | Delhi Journal of Ophthalmology |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.7869/djo.553 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850204532932345856 |
|---|---|
| author | Jatinder Bali Ojasvini Bali |
| author_facet | Jatinder Bali Ojasvini Bali |
| author_sort | Jatinder Bali |
| collection | DOAJ |
| description | Glaucoma, the leading cause of irreversible blindness, blinds causes irreversible blindness in 4.0 million people worldwide. In India the estimated number of glaucoma patients is 12 million which is one fifth of the global morbidity of glaucoma.1 Elevation of intraocular pressure (IOP) is the only proven modifiable risk factor for most forms of glaucoma. Different etiological mechanisms have been proposed for increased IOP. Aqueous humor (AH) drainage from conventional or trabecular and uveoscleral pathway is a proven cause in most glaucoma patients and especially so in primary open angle glaucoma. IOP reduction slows vision loss and remains the mainstay of treatment for all types of glaucoma. Rho kinase is a serine/threonine protein kinase. It is a downstream effector of Rho GTPase, a Ras superfamily GTPase. it has a role in the conventional path of aqueous drainage. Rho Kinase (ROCK) inhibitors Ripasudil, K-115 and Netarsudil, AR-13503 have recently been approved for ophthalmological use in therapy of glaucoma as IOP-lowering agents. This is a brief overview of the Rho Kinase (ROCK) inhibitors. |
| format | Article |
| id | doaj-art-64d4d573923d4665bef9300b2d9c26a5 |
| institution | OA Journals |
| issn | 0972-0200 2454-2784 |
| language | English |
| publishDate | 2020-04-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Delhi Journal of Ophthalmology |
| spelling | doaj-art-64d4d573923d4665bef9300b2d9c26a52025-08-20T02:11:16ZengWolters Kluwer Medknow PublicationsDelhi Journal of Ophthalmology0972-02002454-27842020-04-01304717410.7869/djo.553Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitorsJatinder BaliOjasvini BaliGlaucoma, the leading cause of irreversible blindness, blinds causes irreversible blindness in 4.0 million people worldwide. In India the estimated number of glaucoma patients is 12 million which is one fifth of the global morbidity of glaucoma.1 Elevation of intraocular pressure (IOP) is the only proven modifiable risk factor for most forms of glaucoma. Different etiological mechanisms have been proposed for increased IOP. Aqueous humor (AH) drainage from conventional or trabecular and uveoscleral pathway is a proven cause in most glaucoma patients and especially so in primary open angle glaucoma. IOP reduction slows vision loss and remains the mainstay of treatment for all types of glaucoma. Rho kinase is a serine/threonine protein kinase. It is a downstream effector of Rho GTPase, a Ras superfamily GTPase. it has a role in the conventional path of aqueous drainage. Rho Kinase (ROCK) inhibitors Ripasudil, K-115 and Netarsudil, AR-13503 have recently been approved for ophthalmological use in therapy of glaucoma as IOP-lowering agents. This is a brief overview of the Rho Kinase (ROCK) inhibitors.https://journals.lww.com/10.7869/djo.553glaucomanetarsudilrho kinase |
| spellingShingle | Jatinder Bali Ojasvini Bali Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors Delhi Journal of Ophthalmology glaucoma netarsudil rho kinase |
| title | Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors |
| title_full | Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors |
| title_fullStr | Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors |
| title_full_unstemmed | Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors |
| title_short | Latest Update in Glaucoma: The first approvals for Rho Kinase inhibitors |
| title_sort | latest update in glaucoma the first approvals for rho kinase inhibitors |
| topic | glaucoma netarsudil rho kinase |
| url | https://journals.lww.com/10.7869/djo.553 |
| work_keys_str_mv | AT jatinderbali latestupdateinglaucomathefirstapprovalsforrhokinaseinhibitors AT ojasvinibali latestupdateinglaucomathefirstapprovalsforrhokinaseinhibitors |